Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study

OBJECTIVE: To compare anti-TNF dose escalation, DMARD and/or glucocorticoid intensification, switches to another biologic, and drug and drug-related costs over 12 and 18 months for rheumatoid arthritis (RA) patients initiating etanercept (ETN), adalimumab (ADA), or infliximab (IFX) in routine clinic...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Open Rheumatol J
Autori principali: Thorne, Carter, Boire, Gilles, Chow, Andrew, Garces, Kirsten, Liu, Fang, Poulin-Costello, Melanie, Walker, Valery, Haraoui, Boulos
Natura: Artigo
Lingua:Inglês
Pubblicazione: Bentham Open 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5744265/
https://ncbi.nlm.nih.gov/pubmed/29296125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1874312901711010123
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi